Business
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
PURCHASE, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its sixth
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its sixth “Conversations” video podcast, which features an interactive discussion with retinal specialists about dry age-related macular degeneration (dry AMD) and the current treatment landscape. Dry AMD is caused by a degeneration of the macula and gradual loss of central vision. An estimated 1.5 million people in the United States are affected by late-stage dry AMD, which can result in permanent vision loss. C. Gustavo De Moraes, M.D., Ph.D., MPH, associate professor of clinical ophthalmology at Columbia University and chief medical officer of Ora, a CRO focused on ophthalmology, moderates this discussion of the pathologic drivers of dry AMD, the treatment landscape, clinical rationale for sigma-2 (σ-2) receptor modulators and the ongoing MAGNIFY phase 2 trial of CT1812 in geographic atrophy secondary to dry AMD. Panelists include Anthony Caggiano, M.D., Ph.D., Cognition Therapeutics’ chief medical officer and two leading industry experts on research and treatment of retinal disease. Episode 6: “Geographic Atrophy: New Strategies to Protect the Retina” features: Jeffrey S. Heier, M.D., Director of the Vitreoretinal Service & Retina Research at Ophthalmic Consultants of BostonPeter K. Kaiser, M.D., FASRS, Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at [email protected]. We’d love to hear your thoughts. About CT1812CT1812 is an experimental orally delivered small molecule sigma-2 (σ-2) receptor modulator designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex. The σ-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with soluble beta amyloid (Aβ) oligomers, oxidative stress and other stressors. Cognition’s clinical program will assess if regulating these processes by modulating the σ-2 receptor with CT1812 can maintain homeostatic function. About Geographic Atrophy Secondary to Dry AMDDry AMD, one of two forms...